Cargando…

High PD‐L1 level of advanced hepatic lymphoepithelioma‐like carcinoma response favorably to lenvatinib plus toripalimab

Lymphoepithelioma‐like carcinoma (LELC) is an uncommon subtype of primary liver cancer with predominant lymphocyte infiltration and a relatively favorable outcome. However, no standard treatment for advanced hepatic LELC has been established. Here, we give a first report of a 60‐year‐old man with ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Yueting, Dang, Zhuyi, Xu, Hang, Yuan, Yunlong, Chen, Ye, Li, Zhiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128174/ https://www.ncbi.nlm.nih.gov/pubmed/35298067 http://dx.doi.org/10.1111/cas.15339

Ejemplares similares

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Safety and feasibility of toripalimab plus lenvatinib with or without radiotherapy in advanced BTC
por: Wang, Yunchao, et al.
Publicado: (2023)

Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Xu, Yu-Jie, et al.
Publicado: (2021)

Hepatic Arterial Infusion Chemotherapy Combined With PD-1 Inhibitors Plus Lenvatinib Versus PD-1 Inhibitors Plus Lenvatinib for Advanced Hepatocellular Carcinoma
por: Mei, Jie, et al.
Publicado: (2021)

Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: real-world study
por: Qu, Wei-Feng, et al.
Publicado: (2022)

PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
por: Xu, Yongkang, et al.
Publicado: (2022)

Primary Pulmonary Lymphoepithelioma-Like Carcinoma Response Favorably To Nivolumab: A Case Report
por: Qiu, Zhi-Xin, et al.
Publicado: (2019)

Toripalimab in advanced biliary tract cancer
por: Li, Wei, et al.
Publicado: (2022)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
por: Wang, Jinfeng, et al.
Publicado: (2023)

PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma
por: Zhang, Xuanye, et al.
Publicado: (2022)

Lymphoepithelioma-Like Carcinoma of the Colon
por: Mori, Yasuharu, et al.
Publicado: (2013)

Lymphoepithelioma-like carcinoma of the breast
por: Nankin, Nils L., et al.
Publicado: (2015)

Lymphoepithelioma-like carcinoma of the skin
por: Oliveira, Cristiano Claudino, et al.
Publicado: (2018)

EBV-associated lymphoepithelioma-like thyroid carcinoma with favorable outcome: case report with cytopathologic and histopathologic study
por: Liu, Chih-Yi, et al.
Publicado: (2018)

Favorable response of primary pulmonary lymphoepithelioma-like carcinoma to sintilimab combined with chemotherapy: A case report
por: Zeng, Shu-Ying, et al.
Publicado: (2022)

Hepatocellular Carcinoma with Radiological Progression: Lenvatinib Plus PD-1 Inhibitor Combined with Microwave Ablation and Synchronous Transarterial Chemoembolization
por: Shi, Qin, et al.
Publicado: (2023)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Partial Response After Toripalimab Plus Anlotinib for Advanced Metaplastic Breast Carcinoma: A Case Report
por: Fu, Yang, et al.
Publicado: (2022)

Toripalimab: the First Domestic Anti-Tumor PD-1 Antibody in China
por: Zhang, Lin, et al.
Publicado: (2022)

Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
por: Makker, Vicky, et al.
Publicado: (2020)

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study
por: Cai, Mingyue, et al.
Publicado: (2022)

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
por: Chang, Xiujuan, et al.
Publicado: (2023)

PD-L1 expression in pulmonary lymphoepithelioma-like carcinoma: is it a prognostic biomarker?
por: Li, Wen, et al.
Publicado: (2022)

Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report
por: Huang, Kai-Kai, et al.
Publicado: (2022)

Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications
por: Sun, Xuqi, et al.
Publicado: (2022)

Lymphoepithelioma-like Carcinoma of the Urinary Bladder
por: Yun, Han Ki, et al.
Publicado: (2010)

Lymphoepithelioma-like Carcinoma (LELC) of the Prostate
por: Eisa, Waleed, et al.
Publicado: (2016)

Lymphoepithelioma-like carcinoma of the uterine cervix
por: Yun, Hyun Sil, et al.
Publicado: (2017)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Checkpoint Inhibition in the Treatment of Unresectable, Advanced Lymphoepithelioma-like Hepatocellular Carcinoma
por: Hermel, David J., et al.
Publicado: (2021)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
por: Xu, Yongkang, et al.
Publicado: (2023)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
por: Hunt, Jonathan T., et al.
Publicado: (2021)

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
por: Shi, Guo-Ming, et al.
Publicado: (2023)

Severe cumulative skin toxicity during toripalimab combined with vemurafenib following toripalimab alone
por: Zhou, Hong, et al.
Publicado: (2023)

Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review
por: Lei, Yanna, et al.
Publicado: (2021)

Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
por: Cao, Yanshuo, et al.
Publicado: (2022)

Lymphoepithelioma-Like Carcinoma of the Stomach with Epithelioid Granulomas
por: Tamura, Toshihisa, et al.
Publicado: (2010)

Unusual presentation of pulmonary lymphoepithelioma‐like carcinoma
por: Oi, Ryoko, et al.
Publicado: (2016)

Mixed lymphoepithelioma-like carcinoma and adenocarcinoma of the gallbladder
por: Choi, Nam Kyu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_930jb1j17tnje9qhta9d07a31h